Joel A. Fernandes
Geen lopende functies
Profiel
Joel A.
Fernandes formerly worked at Innoviva, Inc., as Associate Director-Finance from 2005 to 2006, Innoviva, Inc., as Associate Director-Finance, ALZA Corp., as Assistant Controller from 1999 to 2002, KLA Corp., as Senior Manager-Corporate Finance from 2002 to 2005, and Threshold Pharmaceuticals, Inc., as Senior Vice President-Finance & Controller.
Mr. Fernandes received his graduate degree from Manchester College.
Eerdere bekende functies van Joel A. Fernandes
| Bedrijven | Functie | Einde |
|---|---|---|
| INNOVIVA, INC. | Corporate Officer/Principal | 01-03-2006 |
| KLA CORPORATION | Corporate Officer/Principal | 01-01-2005 |
| ALZA CORPORATION | Corporate Officer/Principal | 01-01-2002 |
| INNOVIVA, INC. | Corporate Officer/Principal | - |
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Director of Finance/CFO | - |
Opleiding van Joel A. Fernandes
| Manchester College | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| KLA CORPORATION | Electronic Technology |
| INNOVIVA, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
ALZA Corp.
 ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
